Abstract
Background/Objective: Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. The purpose of the present trial was to investigate its effect in preventing postoperative atrial fibrillation (POAF) after on-pump coronary artery bypass graft (CABG) surgery.
Methods: In the current prospective, randomized, (1 active: 2 control), single-blind (outcome assessors), single-centre clinical trial we recruited consecutive eligible patients scheduled for elective on-pump CABG. Participants were assigned to receive either oral ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge, or to receive usual care. Patients were monitored for the development of POAF.
Results: We enrolled 102 patients. Significantly lower incidence of POAF was noted in the ranolazine group compared with the control group (3 out of 34 patients, 8.8%, vs 21 out of 68 patients, 30.8%; p< 0.001). Mean values of left atrial diameter and left ventricular ejection fraction between the control and the ranolazine group were not significantly different.
Conclusion: Our findings suggest a protective role of oral ranolazine when administered in a moderate dose preoperatively in patients undergoing on-pump CABG surgery. Future studies based on a wider sample of patients will eventually support our conclusions.
Keywords: Ranolazine, atrial fibrillation, postoperative, coronary artery bypass graft surgery, prevention.
Current Vascular Pharmacology
Title:Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery
Volume: 11 Issue: 6
Author(s): Georgios I. Tagarakis, Isaac Aidonidis, Stella S. Daskalopoulou, Vassilios Simopoulos, Vassilios Liouras, Marios E. Daskalopoulos, Charalampos Parisis, Kiriaki Papageorgiou, Ioannis Skoularingis, Filippos Triposkiadis, Paschalis-Adam Molyvdas and Nikolaos B. Tsilimingas
Affiliation:
Keywords: Ranolazine, atrial fibrillation, postoperative, coronary artery bypass graft surgery, prevention.
Abstract: Background/Objective: Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. The purpose of the present trial was to investigate its effect in preventing postoperative atrial fibrillation (POAF) after on-pump coronary artery bypass graft (CABG) surgery.
Methods: In the current prospective, randomized, (1 active: 2 control), single-blind (outcome assessors), single-centre clinical trial we recruited consecutive eligible patients scheduled for elective on-pump CABG. Participants were assigned to receive either oral ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge, or to receive usual care. Patients were monitored for the development of POAF.
Results: We enrolled 102 patients. Significantly lower incidence of POAF was noted in the ranolazine group compared with the control group (3 out of 34 patients, 8.8%, vs 21 out of 68 patients, 30.8%; p< 0.001). Mean values of left atrial diameter and left ventricular ejection fraction between the control and the ranolazine group were not significantly different.
Conclusion: Our findings suggest a protective role of oral ranolazine when administered in a moderate dose preoperatively in patients undergoing on-pump CABG surgery. Future studies based on a wider sample of patients will eventually support our conclusions.
Export Options
About this article
Cite this article as:
Tagarakis I. Georgios, Aidonidis Isaac, Daskalopoulou S. Stella, Simopoulos Vassilios, Liouras Vassilios, Daskalopoulos E. Marios, Parisis Charalampos, Papageorgiou Kiriaki, Skoularingis Ioannis, Triposkiadis Filippos, Molyvdas Paschalis-Adam and Tsilimingas B. Nikolaos, Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/157016111106140128123506
DOI https://dx.doi.org/10.2174/157016111106140128123506 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Cell Immunity in Inflammatory Vasculitis
Current Immunology Reviews (Discontinued) Cryoballoon Ablation of Atrial Fibrillation: State of the Art 10 Years After Its Invention
Recent Patents on Cardiovascular Drug Discovery Leukotrienes and Atherosclerosis
Current Drug Targets Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine Novel uses of Imaging in AF Ablation
Recent Patents on Cardiovascular Drug Discovery Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress
Cardiovascular & Hematological Agents in Medicinal Chemistry Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued) The Saphenous Vein as a Bypass Conduit: The Potential Role of Vascular Nerves in Graft Performance
Current Vascular Pharmacology The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Cardiovascular & Hematological Disorders-Drug Targets Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Oxidative Stress in the Pathogenesis/Treatment of Atherosclerosis
Current Nutrition & Food Science Fluid and Electrolyte Disorders in the Newborn: Sodium and Potassium
Current Pediatric Reviews Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology